New application of fluoxetine combined with ziprasidone in prevention and treatment of central hyperthermia

A technology of ziprasidone and fluoxetine, which is applied in the treatment of central hyperthermia after central nervous system injury, fluoxetine combined with ziprasidone, in the field of prevention, can solve the problems of unfavorable recovery of brain injury patients, local temperature rise, There are no problems such as therapeutic drugs to achieve the effects of eliminating adverse effects, improving tolerance, and reducing mortality

Active Publication Date: 2019-03-19
THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Both infectious hyperthermia and dehydrating fever have specific treatment methods, while central hyperthermia is caused by the up-regulation of the temperature regulation center of the hypothalamus PO / AH area, and there is currently no specific therapeutic drug in clinical practice.
Nerve cells are extremely intolerable to local temperature rise, and the persistence of high fever is extremely detrimental to the rehabilitation of brain-injured patients.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of fluoxetine combined with ziprasidone in prevention and treatment of central hyperthermia
  • New application of fluoxetine combined with ziprasidone in prevention and treatment of central hyperthermia
  • New application of fluoxetine combined with ziprasidone in prevention and treatment of central hyperthermia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] A fluoxetine combined with ziprasidone injection, the formula is: fluoxetine 2g / L, ziprasidone 2.5g / L, citric acid 300mg / L, malic acid 300mg / L. The preparation method is:

[0028] (1) Mix each raw material in proportion with 1 / 2 volume of water for injection, add activated carbon for adsorption, and filter for decarburization;

[0029] (2) Mix the solution in step (1) with the remaining water for injection, add activated carbon for adsorption, and filter for decarburization;

[0030] (3) Filter the dosing liquid in step (2) with a filter of 0.22 micron, and fill it;

[0031] (4) Sterilized at 120°C for 45 minutes to prepare.

[0032] The product was placed at 40°C and 4°C for 12 hours, and observed monthly, no crystallization was found in the product. After 12 months, it was tested that the content of active ingredients was greater than 99.5%.

Embodiment 2

[0033] Example 2 Therapeutic effect of fluoxetine combined with ziprasidone on central hyperthermia in rats with traumatic brain injury

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides novel application of fluoxetine and ziprasidone combination in preventing and treating central heat due to acute injury of central nervous system. For an animal with cerebral trauma, the fluoxetine and ziprasidone combination can improve central fever and control intracranial pressure rise due to cerebral fever, may effectively reduce apoptosis of cerebral injury focal peripheral nerves and reduce animal morality relevant to cerebral injury and is safe and free of significant toxic and side effects.

Description

technical field [0001] The present invention relates to the new application of 5-HT reuptake inhibitors and 5-HT1a receptor agonist antidepressants, in particular to the effect of fluoxetine combined with ziprasidone in the prevention and treatment of central hyperthermia after central nervous system injury use. Background technique [0002] Acute central nervous system injuries include traumatic brain injury, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral infarction, which are characterized by high mortality and disability rates, and currently there is no specific treatment. After central nervous system injury, patients often develop high fever. The main causes include infectious, dehydrating fever, and central hyperthermia. Both infectious hyperthermia and dehydrating fever have specific treatments, while central hyperthermia is caused by the up-regulation of the thermoregulatory set point of the hypothalamic PO / AH area thermoregulatory center. Currently, ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/496A61P29/00A61P25/00A61K31/138
CPCA61K9/0019A61K9/08A61K31/138A61K31/496A61K47/12A61K2300/00
Inventor 谭亮李荣伟马康张旋陈前伟唐俊刘昕冯华
Owner THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap